Trevi Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Trevi TherapeuticsDer Gewinn des Unternehmens wird voraussichtlich um 9.1% pro Jahr sinken, während der Jahresumsatz voraussichtlich um 85.4% pro Jahr wachsen wird. Der Gewinn pro Aktie wird voraussichtlich zurückgehen.

Wichtige Informationen

-9.1%

Wachstumsrate der Gewinne

-3.5%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	27.6%
Wachstumsrate der Einnahmen	85.4%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	09 May 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

We Think Trevi Therapeutics (NASDAQ:TRVI) Can Afford To Drive Business Growth

May 24

Trevi Therapeutics (NASDAQ:TRVI) Is In A Good Position To Deliver On Growth Plans

Jan 27

Gewinn- und Umsatzwachstumsprognosen

NasdaqGM:TRVI - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	1	-79	-64	N/A	5
12/31/2025	N/A	-53	-57	N/A	5
12/31/2024	N/A	-43	-47	-39	5
3/31/2024	N/A	-34	-34	-34	N/A
12/31/2023	N/A	-29	-32	-32	N/A
9/30/2023	N/A	-27	-32	-32	N/A
6/30/2023	N/A	-27	-33	-33	N/A
3/31/2023	N/A	-28	-29	-29	N/A
12/31/2022	N/A	-29	-28	-28	N/A
9/30/2022	N/A	-32	-28	-28	N/A
6/30/2022	N/A	-31	-27	-27	N/A
3/31/2022	N/A	-33	-28	-28	N/A
12/31/2021	N/A	-34	-29	-29	N/A
9/30/2021	N/A	-35	-32	-32	N/A
6/30/2021	N/A	-35	-31	-31	N/A
3/31/2021	N/A	-33	-32	-32	N/A
12/31/2020	N/A	-33	-29	-29	N/A
9/30/2020	N/A	-30	-26	-26	N/A
6/30/2020	N/A	-30	-27	-27	N/A
3/31/2020	N/A	-29	-24	-24	N/A
12/31/2019	N/A	-27	-23	-23	N/A
9/30/2019	N/A	-28	-22	-22	N/A
6/30/2019	N/A	-27	-18	-18	N/A
3/31/2019	N/A	-27	-19	-18	N/A
12/31/2018	N/A	-26	-18	-18	N/A
9/30/2018	N/A	-22	-16	-16	N/A
12/31/2017	N/A	-13	N/A	-8	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: TRVI wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: TRVI wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: TRVI wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: TRVI wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Hohe Wachstumseinnahmen: TRVI wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von TRVI in 3 Jahren voraussichtlich hoch sein wird

Trevi Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased to US$8.75

Price target increased to US$10.00

Price target decreased to US$8.67

Price target decreased to US$10.00

Forecast to breakeven in 2025

Price target raised to US$11.67

Recent updates

We Think Trevi Therapeutics (NASDAQ:TRVI) Can Afford To Drive Business Growth

Trevi Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

Trevi Therapeutics, Inc. to Report Q4, 2023 Results on Mar 20, 2024

Trevi Therapeutics (NASDAQ:TRVI) Is In A Good Position To Deliver On Growth Plans

New minor risk - Share price stability

Trevi Therapeutics, Inc. Announces the Initiation of its Phase 2b CORAL Clinical Trial of Haduvio™ for Chronic Cough in Idiopathic Pulmonary Fibrosis (IPF)

New minor risk - Market cap size

Trevi Therapeutics, Inc. Announces the Initiation of its Phase 2a RIVER Clinical Trial of Haduvio™? for Refractory Chronic Cough

Trevi Therapeutics, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Trevi Therapeutics, Inc. Announces Results from Phase 2b/3 Prism Open-Label Extension Study of Haduvio in Prurigo Nodularis

Trevi Therapeutics, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Insufficient new directors

Trevi Therapeutics, Inc. to Report Q1, 2023 Results on May 11, 2023

Price target decreased to US$8.75

Trevi Therapeutics, Inc. Appoints David Clark as Chief Medical Officer

Trevi Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $54.990753 million.

Trevi Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $50 million.

Trevi Therapeutics Announces Positive Data from Full Set of Subjects in Phase 2 CANAL Trial of Haduvio™ in the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis

Trevi adds 19% on full data set from mid-stage cough study

Trevi Therapeutics: Moving Forward

Price target increased to US$10.00

Trevi Therapeutics Inc. Reports Positive Results from the Ph2b/3 PRISM Trial of Haduvi in Treatment of Prurigo Nodularis

Trevi Therapeutics, Inc.(NasdaqGM:TRVI) dropped from Russell Microcap Value Index

Trevi Therapeutics, Inc. to Report Q1, 2022 Results on May 12, 2022

Trevi Therapeutics, Inc., Annual General Meeting, Jun 23, 2022

Price target decreased to US$8.67

Trevi Therapeutics, Inc. announced that it has received $54.999998 million in funding from Fairmount Funds Management LLC, Frazier Management, L.L.C., New Enterprise Associates, Inc., VR Adviser, LLC

Trevi Therapeutics, Inc. announced that it expects to receive $54.999998 million in funding from Fairmount Funds Management LLC, Frazier Management, L.L.C., New Enterprise Associates, Inc., VR Adviser, LLC

Is Trevi Therapeutics (NASDAQ:TRVI) Using Too Much Debt?

Trevi Therapeutics, Inc. Reports Statistically Significant Result on Interim Analysis from the Ph2 Canal Trial of Nalbuphine Er in the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis

Trevi Therapeutics, Inc. Completes Enrollment for Phase 2b/3 PRISM Study in Chronic Pruritus in PN

Trevi Therapeutics Announces Clinical Trial Updates for Lead Indications

Price target decreased to US$10.00

Forecast to breakeven in 2025

Chief Financial Officer has left the company

Trevi Therapeutics, Inc. to Report Q4, 2020 Results on Mar 25, 2021

New 90-day low: US$2.36

Price target raised to US$11.67

Trevi Therapeutics Appoints William Forbe as Chief Development Officer

Trevi has a new development chief

New 90-day low: US$2.65

New 90-day low: US$2.97

New 90-day low: US$3.10

Trevi Therapeutics, Inc. to Report Q3, 2020 Results on Nov 11, 2020

New 90-day low: US$3.49

New 90-day low - US$3.50

Trevi Therapeutics, Inc. to Report Q2, 2020 Results on Aug 13, 2020

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken